Pharmaceuticals

The North Carolina biotech's oral Nrf2/Bach1 modulator HPPD has received FDA Orphan Drug Designation for sickle cell disease, backed by preclinical fetal haemoglobin

Vaxcyte priced concurrent equity and $500m convertible note offerings to bankroll its 31-valent pneumococcal vaccine through Phase 3 and potential US launch.

The FURVENT trial's firmonertinib failed to beat chemotherapy on BICR-assessed progression-free survival in first-line EGFR exon 20 insertion-mutant NSCLC.

Jupiter Neurosciences has begun dosing in the RESET trial of JOTROL in Parkinson's disease while simultaneously exploring a sale or licensing of its assets.

The Brisbane biotech adds at least one new target to its Lilly collaboration, with total milestone-contingent deal value potentially exceeding $870 million.

BridgeBio will share 24-week Phase 3 CALIBRATE trial data on encaleret in ADH1, covering bone turnover and patient-reported outcomes, at ASBMR in Boston.

The Leiden spin-out is advancing RTX-001, a once-daily oral pericyte-targeting candidate, toward first-in-human trials in a condition with no

Genmab and AbbVie say their EPCORE DLBCL-2 trial is the first Phase 3 bispecific study to hit a PFS endpoint in frontline diffuse large

Phase 1b open-label extension data show no clinically meaningful motor progression in 12 Parkinson's patients after a full year of daily oral rexaceract.

A Delaware district court found two claims of United Therapeutics' '327 patent valid and infringed, putting YUTREPIA's PH-ILD label at risk.

The Nasdaq-listed ophthalmic biotech has acquired its existing IOL manufacturer from Santen, securing Phase 3 supply and a route to premium lens options.

MiNK will present two posters at SITC covering checkpoint-resistant colorectal cancer and senescent tumour-cell clearance using its iNKT platform.

Phase 2 data show Rina-S achieved a 45.9% objective response rate and 12.1-month median duration of response in heavily pretreated platinum

Elutia has cleared its final 2026 funding milestone, receiving the full $8m holdback from its BioEnvelope sale with no indemnity claims.

Climb Bio will present preliminary PrisMN Phase 2 data on budoprutug in membranous nephropathy at ASN Kidney Week in Denver this October.

London PE firm Samfara has completed its first acquisition, buying Danish cGMP manufacturer Chr. Olesen Synthesis, which specialises in buprenorphine and lisdexamfetamine

New data presented at MDS 2026 show ecopipam cut tic severity by 45.6% at 18 months, with no new safety signals in an ongoing

Novo Nordisk presented STEP UP sub-analysis at EASD 2026 showing Wegovy reduced mean liver fat from 8.8% to 3.1% over 72 weeks

Phase 2 AMETHYST data show over a quarter of litifilimab-treated patients achieved clear or almost clear skin; Phase 3 results are due in H1

The Amsterdam biotech reported a 38% rise in active methotrexate inside immune cells, supporting a €10m Series A and a Phase 2a trial in 2027.